In January 2017, Daiichi Sankyo received exclusive development, manufacturing and commercialization rights for axicabtagene ciloleucel in Japan from California-based Kite, a Gilead Company. The Japan NDA submission is
According to the company, the new programme is based on data showing that ST266 significantly decreased the inflammatory response of a body in a range of diseases and
The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and
The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infectious diseases. Translate Bio
ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based
Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Sanofi, BD and bioMérieux are part of the consortium. The firms are working
This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of technology to support patients
Under the deal, Vir can non-exclusively access Xencor’s Xtend Fc technology to expand the half-life of novel antibodies, which are being assessed as potential treatments for patients with
Amneal is ramping up production of hydroxychloroquine sulfate at several of its manufacturing sites and expects to produce approximately 20 million tablets between now and mid-April. Those tablets
Feinstein Institutes researchers have collaborated with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to detect efficient treatments for patients currently hospitalised in moderate and severe conditions with COVID-19. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.